litlas
Log inCreate account

Hiroshi Handa

Active 1977–2024

158
Papers
22,648
Citations
86
h-index
156
i10-index

Citations

Citations per year for Hiroshi Handa1977: 1 citations1978: 2 citations1979: 3 citations1980: 5 citations1981: 8 citations1982: 4 citations1983: 7 citations1984: 7 citations1985: 5 citations1986: 6 citations1987: 5 citations1988: 3 citations1989: 2 citations1990: 5 citations1991: 8 citations1992: 12 citations1993: 7 citations1994: 25 citations1995: 25 citations1996: 21 citations1997: 37 citations1998: 60 citations1999: 86 citations2000: 120 citations2001: 118 citations2002: 161 citations2003: 176 citations2004: 142 citations2005: 148 citations2006: 198 citations2007: 177 citations2008: 187 citations2009: 165 citations2010: 197 citations2011: 202 citations2012: 202 citations2013: 228 citations2014: 187 citations2015: 182 citations2016: 179 citations2017: 213 citations2018: 225 citations2019: 613 citations2020: 782 citations2021: 825 citations2022: 672 citations2023: 477 citations2024: 768 citations2025: 406 citations2026: 8 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,579 citing papers, 31.7% of this breakdownChina: 863 citing papers, 10.6% of this breakdownJapan: 545 citing papers, 6.7% of this breakdownUnited Kingdom: 536 citing papers, 6.6% of this breakdownGermany: 494 citing papers, 6.1% of this breakdownFrance: 302 citing papers, 3.7% of this breakdownItaly: 265 citing papers, 3.3% of this breakdownCanada: 251 citing papers, 3.1% of this breakdownSpain: 183 citing papers, 2.2% of this breakdownSwitzerland: 170 citing papers, 2.1% of this breakdownNetherlands: 148 citing papers, 1.8% of this breakdownAustralia: 143 citing papers, 1.8% of this breakdown
0%31.7%Other 20.3%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology60%
  • Medicine27.7%
  • Immunology and Microbiology4.4%
  • Neuroscience1.8%
  • Agricultural and Biological Sciences1.3%
  • Chemistry1%
  • Other3.8%

Topics

  • Protein Degradation and Inhibitors6.9%
  • Ubiquitin and proteasome pathways5.3%
  • RNA Research and Splicing5.1%
  • Genomics and Chromatin Dynamics4.1%
  • Multiple Myeloma Research and Treatments3.4%
  • RNA modifications and cancer3.1%
  • Other72.1%

Coauthors

All papers

Open in search
  1. Identification of a Primary Target of Thalidomide Teratogenicity

    Authors: Takumi Ito, Hideki Ando, Takayuki Suzuki, Toshihiko Ogura, Kentaro Hotta, Yoshimasa Imamura, Yuki Yamaguchi, Hiroshi Handa - Science 2010 cited by 2,119

  2. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase

    Authors: Mary E. Matyskiela, Gang Lu, Takumi Ito, Barbra Pagarigan, Chin-Chun Lu, Karen Miller, Wei Fang, Naiyu Wang, Derek Nguyen, Jack Houston, Gilles Carmel, Tam Tran, Mariko Riley, Lyn’Al Nosaka, Gabriel C. Lander, Svetlana Gaidarova, Shuichan Xu, Alexander L. Ruchelman, Hiroshi Handa, James Carmichael, Thomas O. Daniel, Brian E. Cathers, Antonia Lopez‐Girona, Philip P. Chamberlain - Nature 2016 cited by 692

  3. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

    Authors: Philip P. Chamberlain, Antonia Lopez‐Girona, Karen Miller, Gilles Carmel, Barbra Pagarigan, B. Chie-Leon, Emily Rychak, Laura G. Corral, Yan Ren, Maria Wang, Mariko Riley, S.L. Delker, Takumi Ito, Hideki Ando, Tomoyuki Mori, Yoshinori Hirano, Hiroshi Handa, Toshio Hakoshima, Thomas O. Daniel, Brian E. Cathers - Nature Structural & Molecular Biology 2014 cited by 515

  4. Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN

    Authors: Anita K. Gandhi, Jian Kang, Courtney G. Havens, Thomas A. Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F. Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O. Daniel, Peter Schäfer, Rajesh Chopra - British Journal of Haematology 2013 cited by 621

  5. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

    Authors: Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa - Chemical Society Reviews 2022 cited by 150

  6. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

    Authors: Antonia Lopez‐Girona, Derek Mendy, Takumi Ito, Karl N. Miller, Anita K. Gandhi, Jian Kang, Satoki Karasawa, Gilles Carmel, Pilgrim J. Jackson, Mahan Abbasian, Ali Mahmoudi, Brian E. Cathers, Emily Rychak, Svetlana Gaidarova, R Chen, Peter Schäfer, Hiroshi Handa, Tom Daniel, Jilly F. Evans, Rajesh Chopra - Leukemia 2012 cited by 798

  7. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

    Authors: Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al‐Samkari, James B. Bussel, Marie Godar, Jaume Ayguasanosa, Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland, Michael Fillitz, Paul Knoebl, Stef Meers, Ismail Amine, Jaromír Gumulec, Antonín Hluší, Jiřı́ Mayer, Philippe Quittet, Jean‐François Viallard, M Betaneli, I Datikashvili-David, Genadi Iosava, Levan Makhaldiani, László Rejtő, Nino Sharashenidze, Stefanie Groepper, Alexander Röth, Aryan Hamed, Árpád Illés, Monica Carpenedo, Andrea Artoni, Monica Bocchia, Barbara Gamberi, Alessandra Borchiellini, Esther Natalie Olíva, Andrea Patriarca, Simona Tomassetti, Yoshitaka Miyakawa, Kiyoshi Ando, Hiroshi Handa, Shinya Katsutani, Kaichi Nishiwaki, Shoko Ito, Tomoki� Ito, Fransien de Boer, A.J. Gerard Jansen, Hanna Ciepłuch, Szymon Fornagiel, Sebastian Grosicki, Maria Soroka‐Wojtaszko, Jacek Treliński, Б. А. Бакиров, Elena Borisenkova, Elena Volodicheva, Yuri Shatokhin, Andrey Proydakov, Maria Aranzazu Alonso, María Eva Mingot‐Castellano, Blanca Sánchez‐González, Blanca Sanchez-Gonzalez, Meltem Aylı, Tuba Hacıbekiroğlu, Ahmet Muzaffer Demir, Meliha Nalçacı, Mehmet Sönmez, Anıl Tombak, Selami Koçak Toprak, Burhan Turgut, Filiz Vural, Münci Yağcı, Fevzi Altuntaş, Mehmet Turgut, Emın Kaya, Nataliya Romanyuk, Vickie McDonald, Syed Rashid Saeed Kazmi, Catherine M. Broome, Spero R. Cataland, Ketan Doshi, Steven R. Lentz, Michael Boxer, Richard Rosenberg, Michael Boxer, Richard Rosenberg - The Lancet 2023 cited by 91

  8. NELF, a Multisubunit Complex Containing RD, Cooperates with DSIF to Repress RNA Polymerase II Elongation

    Authors: Yuki Yamaguchi, Toshiyuki Takagi, Tadashi Wada, Keiichi Yano, Akiko Furuya, Seiji Sugimoto, Jun Hasegawa, Hiroshi Handa - Cell 1999 cited by 842

  9. DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs

    Authors: Takuro Wada, Toshiyuki Takagi, Yuki Yamaguchi, Anwarul Ferdous, Takeshi Imai, Susumu Hirose, Satoru Sugimoto, Keiichi Yano, Grant A. Hartzog, Fred Winston, Stephen Buratowski, Hiroshi Handa - Genes & Development 1998 cited by 747

  10. Redox Regulation of NF-κB Activation: Distinct Redox Regulation Between the Cytoplasm and the Nucleus

    Authors: Yasuaki Kabe, Kozue Ando, Satoshi Hirao, Makoto Yoshida, Hiroshi Handa - Antioxidants and Redox Signaling 2005 cited by 573

  11. P-TEFb-Mediated Phosphorylation of hSpt5 C-Terminal Repeats Is Critical for Processive Transcription Elongation

    Authors: Tomoko Yamada, Yuki Yamaguchi, Naoto Inukai, Sachiko Okamoto, Takashi Mura, Hiroshi Handa - Molecular Cell 2006 cited by 394

  12. Structural basis of thalidomide enantiomer binding to cereblon

    Authors: Tomoyuki Mori, Takumi Ito, Shujie Liu, Hideki Ando, Satoshi Sakamoto, Yuki Yamaguchi, Etsuko Tokunaga, Norio Shibata, Hiroshi Handa, Toshio Hakoshima - Scientific Reports 2018 cited by 128

  13. Molecular mechanisms of thalidomide and its derivatives

    Authors: Takumi Ito, Hiroshi Handa - Japan Academy Series B, Proceedings of the Japan Academy Series B 2020 cited by 116

  14. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon

    Authors: Thang Van Nguyen, J. Eugene Lee, Michael J. Sweredoski, Seung-Joo Yang, Seung-Je Jeon, Joseph S. Harrison, Jung-Hyuk Yim, Sang Ghil Lee, Hiroshi Handa, Brian Kuhlman, Ji-Seon Jeong, Justin M. Reitsma, Chul‐Seung Park, Sonja Hess, Raymond J. Deshaies - Molecular Cell 2016 cited by 179

  15. ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells

    Authors: Junichi Yamamoto, Tetsufumi Suwa, Yuki Murase, Shumpei Tateno, Hirotaka Mizutome, Tomoko Asatsuma‐Okumura, Nobuyuki Shimizu, Tsutomu Kishi, Shuji Momose, Masahiro Kizaki, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa - Nature Chemical Biology 2020 cited by 99

  16. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology

    Authors: Takumi Ito, Yuki Yamaguchi, Hiroshi Handa - Cell chemical biology 2021 cited by 56

  17. NELF and DSIF cause promoter proximal pausing on thehsp70promoter inDrosophila

    Authors: Chwen-Huey Wu, Yuki Yamaguchi, Lawrence R. Benjamin, Maria Horvat‐Gordon, Jodi Washinsky, Espen Enerly, Jan Larsson, Andrew Lambertsson, Hiroshi Handa, David S. Gilmour - Genes & Development 2003 cited by 311

  18. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons

    Authors: Kazuhide Asakawa, Hiroshi Handa, Koichi Kawakami - Nature Communications 2020 cited by 96

  19. Development of a Highly Sensitive Device for Counting the Number of Disease-Specific Exosomes in Human Sera

    Authors: Yasuaki Kabe, Makoto Suematsu, Satoshi Sakamoto, Miwa Hirai, Ikko Koike, Takako Hishiki, Atsushi Matsuda, Yuichi Hasegawa, Koji Tsujita, Masayuki Ono, Naoko Minegishi, Atsushi Hozawa, Yoshinori Murakami, Michiaki Kubo, Makoto Itonaga, Hiroshi Handa - Clinical Chemistry 2018 cited by 80

  20. Evidence that Negative Elongation Factor Represses Transcription Elongation through Binding to a DRB Sensitivity-Inducing Factor/RNA Polymerase II Complex and RNA

    Authors: Yuki Yamaguchi, Naoto Inukai, Takashi Narita, Tadashi Wada, Hiroshi Handa - Molecular and Cellular Biology 2002 cited by 228

  21. p63 is a cereblon substrate involved in thalidomide teratogenicity

    Authors: Tomoko Asatsuma‐Okumura, Hideki Ando, Marco De Simone, Junichi Yamamoto, Tomomi Sato, Nobuyuki Shimizu, Kazuhide Asakawa, Yuki Yamaguchi, Takumi Ito, Luisa Guerrini, Hiroshi Handa - Nature Chemical Biology 2019 cited by 137

  22. DNA damage‐induced cellular senescence is regulated by 53BP1 accumulation in the nuclear foci and phase separation

    Authors: Tsukasa Oda, Nanami Gotoh, Tetsuhiro Kasamatsu, Hiroshi Handa, Takayuki Saitoh, Nobuo Sasaki - Cell Proliferation 2023 cited by 31

  23. DSIF and NELF interact with Integrator to specify the correct post-transcriptional fate of snRNA genes

    Authors: Junichi Yamamoto, Yuri Hagiwara, Kunitoshi Chiba, Tomoyasu Isobe, Takashi Narita, Hiroshi Handa, Yuki Yamaguchi - Nature Communications 2014 cited by 106

  24. Evidence that P‐TEFb alleviates the negative effect of DSIF on RNA polymerase II‐dependent transcription in vitro

    Authors: Takuro Wada, Toshiyuki Takagi, Yuki Yamaguchi, Daisuke Watanabe, Hiroshi Handa - The EMBO Journal 1998 cited by 356